{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T22:28:59Z","timestamp":1760480939743,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Salix"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.transproceed.2014.10.021","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T10:03:34Z","timestamp":1418119414000},"page":"3481-3486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and Tolerability of Rifaximin in Combination With Lactulose in End-stage Liver Disease Patients With MELD Greater Than 20: A Single Center Experience"],"prefix":"10.1016","volume":"46","author":[{"given":"P.S.","family":"Mantry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Graydon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.transproceed.2014.10.021_bib1","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrgastro.2013.99","article-title":"The liver-brain axis in liver failure: neuroinflammation and encephalopathy","volume":"10","author":"Butterworth","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib2","article-title":"Chronic acquired hepatocerebral degeneration, pallidal T1 MRI hyperintensity and manganese in a series of cirrhotic patients","volume":"28","author":"Maffeo","year":"2013","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.transproceed.2014.10.021_bib3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jtemb.2011.07.003","article-title":"Blood manganese levels in patients with hepatic encephalopathy","volume":"25","author":"Zer\u00f3n","year":"2011","journal-title":"J\u00a0Trace Elem Med Biol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib4","series-title":"Hepatology: a textbook of liver disease","first-page":"431","article-title":"Clinical features of hepatic encephalopathy","author":"Weissenborn","year":"2003"},{"issue":"suppl 1","key":"10.1016\/j.transproceed.2014.10.021_bib5","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/S0168-8278(00)80424-9","article-title":"Complications of cirrhosis. III. Hepatic encephalopathy","volume":"32","author":"Butterworth","year":"2000","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib6","series-title":"Schiff's diseases of the liver","first-page":"595","article-title":"Hepatic encephalopathy","author":"Cordoba","year":"2003"},{"key":"10.1016\/j.transproceed.2014.10.021_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/phrs.1997.0198","article-title":"Antibacterial activity of rifaximin reduces the level of benzodiazepine-like compounds in patients with liver cirrhosis","volume":"35","author":"Zeneroli","year":"1997","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.transproceed.2014.10.021_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1592\/phco.28.8.1019","article-title":"Rifaximin for the treatment of hepatic encephalopathy","volume":"28","author":"Lawrence","year":"2008","journal-title":"Pharmacotherapy"},{"issue":"25 Suppl 1","key":"10.1016\/j.transproceed.2014.10.021_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"The burden of hepatic encephalopathy","author":"Poordad","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.transproceed.2014.10.021_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.mcna.2008.03.009","article-title":"Hepatic encephalopathy","volume":"92","author":"Munoz","year":"2008","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.transproceed.2014.10.021_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X11401774","article-title":"Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence","volume":"4","author":"Flamm","year":"2011","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib12","first-page":"617","article-title":"Current trends in the treatment of hepatic encephalopathy","volume":"5","author":"Al Sibae","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.transproceed.2014.10.021_bib13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/bmj.38048.506134.EE","article-title":"Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials","volume":"328","author":"Als-Nielsen","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.transproceed.2014.10.021_bib14","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","article-title":"Hepatic encephalopathy","volume":"96","author":"Blei","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11011-007-9060-7","article-title":"The treatment of hepatic encephalopathy","volume":"22","author":"Morgan","year":"2007","journal-title":"Metab Brain Dis"},{"first-page":"1453","year":"1999","series-title":"Current medical diagnosis & treatment","key":"10.1016\/j.transproceed.2014.10.021_bib16"},{"key":"10.1016\/j.transproceed.2014.10.021_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijantimicag.2008.09.001","article-title":"Do we still need the aminoglycosides?","volume":"33","author":"Durante-Mangoni","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.transproceed.2014.10.021_bib18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/hep.1840080442","article-title":"Liver disease, aminoglycoside antibiotics and renal dysfunction","volume":"8","author":"Leitman","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.transproceed.2014.10.021_bib19","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2001.03958.x","article-title":"Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis","volume":"96","author":"Hampel","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.transproceed.2014.10.021_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","article-title":"Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders","volume":"42","author":"Adachi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transproceed.2014.10.021_bib21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections","volume":"3","author":"Gerard","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"51 Suppl 1","key":"10.1016\/j.transproceed.2014.10.021_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in\u00a0vitro and in\u00a0vivo antibacterial activity \u2014 a review","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.transproceed.2014.10.021_bib23","first-page":"186","article-title":"Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations","volume":"20","author":"Debbia","year":"2008","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.transproceed.2014.10.021_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.transproceed.2014.10.021_bib25","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0011-393X(05)80681-2","article-title":"Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety","volume":"54","author":"Festi","year":"1993","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.transproceed.2014.10.021_bib26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1185\/03007999509111552","article-title":"Rifaximin in the treatment of chronic hepatic encephalopathy","volume":"13","author":"Puxeddu","year":"1995","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.transproceed.2014.10.021_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","article-title":"Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study","volume":"46","author":"Paik","year":"2005","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.transproceed.2014.10.021_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, doubleblind, double-dummy, controlled clinical trial","volume":"38","author":"Mas","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib29","first-page":"53","article-title":"Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a doubleblind clinical study","volume":"49","author":"Loguercio","year":"2003","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib30","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double- blind, randomized trial","volume":"23","author":"Pedretti","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib31","first-page":"403","article-title":"Rifaximine versus neomycin in the treatment of portosystemic encephalopathy","volume":"23","author":"Di Piazza","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1185\/03007999709113333","article-title":"Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomised trial","volume":"13","author":"Miglio","year":"1997","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.transproceed.2014.10.021_bib33","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0b013e328302f470","article-title":"Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis","volume":"20","author":"Jiang","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.transproceed.2014.10.021_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2146\/ajhp070298","article-title":"Rifaximin for the treatment of hepatic encephalopathy","volume":"65","author":"de Melo","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.transproceed.2014.10.021_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1345\/aph.1K436","article-title":"Rifaximin for treatment of hepatic encephalopathy","volume":"43","author":"Maclayton","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.transproceed.2014.10.021_bib36","first-page":"57","article-title":"Rifaximin in the treatment of hepatic encephalopathy","volume":"4","author":"Giacomo","year":"1993","journal-title":"Eur J Clin Res"},{"key":"10.1016\/j.transproceed.2014.10.021_bib37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy","volume":"52","author":"Leevy","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.transproceed.2014.10.021_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2013.10.018","article-title":"A\u00a0MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding","volume":"146","author":"Reverter","year":"2014","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.transproceed.2014.10.021_bib39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.transproceed.2014.10.021_bib40","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1016\/j.transproceed.2006.10.107","article-title":"Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy","volume":"38","author":"Neff","year":"2006","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1016\/j.transproceed.2014.10.021_bib41","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1016\/j.transproceed.2010.09.173","article-title":"Rifaximin for the treatment of hepatic encephalopathy","volume":"42","author":"Mantry","year":"2010","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1016\/j.transproceed.2014.10.021_bib42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","article-title":"Mechanisms, diagnosis and management of hepatic encephalopathy","volume":"7","author":"Prakash","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.transproceed.2014.10.021_bib43","first-page":"315","article-title":"The role of rifaximine in the prevention of the spontaneous bacterial peritonitis","volume":"117","author":"D\u0103nulescu","year":"2013","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"issue":"6","key":"10.1016\/j.transproceed.2014.10.021_bib44","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1572-0241.2003.07475.x","article-title":"Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension","volume":"98","author":"Gunnarsdottir","year":"2003","journal-title":"Am J Gastroenterol"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451401121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113451401121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:28:47Z","timestamp":1758576527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113451401121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S004113451401121X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.021","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Rifaximin in Combination With Lactulose in End-stage Liver Disease Patients With MELD Greater Than 20: A Single Center Experience","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2014.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}